Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Staphylokinase variant

A technology of staphylokinase and variants, applied in the fields of peptide/protein components, peptides, chemical instruments and methods, etc.

Inactive Publication Date: 2013-07-17
凝血基因公司
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, unlike SK or rtPA, taking Sak does not lead to fibrinogen degradation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Staphylokinase variant
  • Staphylokinase variant

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0039] In order to prepare modified staphylokinase variants, the above preparation method may further include the following steps:

[0040] (iii) modifying the staphylokinase variant isolated in (ii).

[0041] In one embodiment, the step of modifying the staphylokinase variant comprises pegylation of the staphylokinase molecule.

[0042] All suitable hosts or host cells and accompanying host cell culture media are contemplated. Non-limiting examples of host cells include: Escherichia coli, Saccharomyces (such as Saccharomyces cerevisiae), Schizosaccharomyces (such as S. pombe), Hansenula (such as polymorpha), insect cells (such as Spodoptera frugiperda) And mammalian cells (such as COS cells, CHO cells).

Embodiment

[0044] Staphylokinase variant preparation

[0045] Molecular cloning, expression, (recombinant) production and purification of staphylokinase and variants thereof were performed essentially as described in detail in any one of EP0525252A1, WO 93 / 13209, WO 96 / 21016 and WO 99 / 40198.

[0046] In vitro fibrinolytic / thrombolytic activity

[0047] The specific activity of the staphylokinase shown in SEQ ID NO: 1 determined in the chromogenic thrombolytic assay was 55±15 kU / mg, which was much lower than that of wild-type SakSTAR (153±33 kU / mg). Chromogenic analysis was performed essentially as described in Example 2.5 of WO 99 / 40198 using S2403 as the chromogenic substrate.

[0048] In contrast, the concentration required for staphylokinase shown in SEQ ID NO: 1 to induce 50% clot lysis in human plasma is similar to the concentration of SakSTAR required (the concentration of SEQ ID NO: 1 is 360 ± 30 ng / mL and the concentration of SakSTAR is 343±35ng / mL). The assay was performed es...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an optimized thrombolytically or fibrinolytically active staphylokinase variant exhibiting low T-cell immunogenicity and reduced clearance by circulating antibodies that can be expressed at high levels.

Description

field of invention [0001] The present invention relates to optimized staphylokinase variants with thrombotic or fibrinolytic activity, low T-cell immunogenicity and low clearance by circulating antibodies expressing high levels. Background technique [0002] Administration of fibrinolytic agents early in the onset of symptoms of myocardial ischemia can protect myocardial tissue, prevent secondary complications caused by myocardial infarction (congestive heart failure, arrhythmia, etc.), and most importantly - save life. The two most commonly used fibrinolytic agents are streptokinase (SK) and recombinant tissue plasminogen activator (rtPA). Despite the advantage of very low cost, SK is not as effective as rtPA (or mutants of rt-PA) in terms of arterial patency and 30-day mortality (the difference in mortality is maintained for at least two years) with concomitant hypotension , allergic reactions and neutralizing antibodies. Conversely, because rtPA is relatively expensive ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/31
CPCA61K38/00C07K14/31
Inventor 德塞尔·科隆
Owner 凝血基因公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com